AZD4041

AZD4041 is an orally administered small molecule that acts as a highly selective antagonist of the orexin 1 receptor (OX1R). It was developed primarily for the treatment of opioid use disorder (OUD), with additional investigation in smoking withdrawal. The drug was designed to provide a non-opioid alternative for OUD by targeting the orexin system, which is implicated in addiction and reward pathways. Unlike less selective agents, AZD4041’s high selectivity for OX1 over OX2 receptors aimed to minimize sedative or hypnotic side effects. Development was led by AstraZeneca in partnership with Eolas Therapeutics and MedImmune. Clinical development reached Phase II before being discontinued due to drug-drug interaction concerns identified during trials involving itraconazole, an antifungal agent[1][5][7].